Collegium Pharmaceutical (COLL) director receives 8,741 RSU grant, now holds 71,000 shares

Rhea-AI Filing Summary

BOHLIN GAREN G reported acquisition or exercise transactions in this Form 4 filing.

Collegium Pharmaceutical director Garen G. Bohlin received an equity award in the form of restricted stock units. The grant covers 8,741 RSUs, each representing one share of common stock, increasing his direct holdings to 71,000 shares. The RSUs vest on the earlier of May 14, 2027 or the company’s 2027 Annual Meeting of Shareholders, contingent on continued board service. Settlement will occur in shares of common stock at vesting or, if elected, upon the end of board service, death, disability, or a change in control.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BOHLIN GAREN G

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	8,741	$0.00	--

Holdings After Transaction: Common Stock — 71,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 8,741 RSUs Shares after transaction: 71,000 shares Grant price: $0.00 per share +1 more

4 metrics

RSUs granted 8,741 RSUs Equity award to director on May 14, 2026

Shares after transaction 71,000 shares Total direct common stock holdings post-grant

Grant price $0.00 per share Compensation grant with no cash paid by director

RSU vesting date May 14, 2027 Vests on this date or at 2027 Annual Meeting, whichever is earlier

Key Terms

restricted stock units ("RSUs"), Annual Meeting of Shareholders, change in control

3 terms

restricted stock units ("RSUs") financial

"Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Annual Meeting of Shareholders financial

"The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

change in control financial

"on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOHLIN GAREN G

(Last) (First) (Middle)

C/O COLLEGIUM PHARMACEUTICAL, INC.

100 TECHNOLOGY CENTER DRIVE

(Street)

STOUGHTON MASSACHUSETTS 02072

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
COLLEGIUM PHARMACEUTICAL, INC [ COLL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A(1)		8,741	A	$0	71,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Colleen Tupper as Attorney-in-Fact for Garen G. Bohlin	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did COLLEGIUM PHARMACEUTICAL (COLL) report for Garen G. Bohlin?

Collegium Pharmaceutical reported an equity grant to director Garen G. Bohlin. He received 8,741 restricted stock units, each equal to one share of common stock, as a compensation-related award with no cash purchase involved.

How many COLLEGIUM PHARMACEUTICAL (COLL) shares does Garen G. Bohlin hold after this Form 4?

After the grant, Garen G. Bohlin holds 71,000 shares of Collegium Pharmaceutical common stock directly. This total includes the 8,741 restricted stock units awarded in the reported transaction, reflecting his updated post-grant equity position.

When do Garen G. Bohlin’s COLLEGIUM PHARMACEUTICAL (COLL) RSUs vest?

The 8,741 RSUs vest on the earlier of May 14, 2027 or Collegium Pharmaceutical’s 2027 Annual Meeting of Shareholders. Vesting is conditioned on Bohlin’s continued service as a director with the company through that date.

How will the COLLEGIUM PHARMACEUTICAL (COLL) RSUs reported on this Form 4 be settled?

Each RSU will be settled in shares of Collegium common stock. Settlement occurs at vesting or, if the director elects, upon the end of board service, death, disability, or a change in control of the company, as described in the award terms.

Is Garen G. Bohlin’s COLLEGIUM PHARMACEUTICAL (COLL) Form 4 transaction a market purchase or sale?

The transaction is not a market trade. It is a compensation-related grant of 8,741 restricted stock units at a stated price of $0.00 per share, categorized as a grant or award acquisition rather than an open-market buy or sell.